Anti-integrin α(v) therapy improves cardiac fibrosis after myocardial infarction by blunting cardiac PW1(+) stromal cells

There is currently no therapy to limit the development of cardiac fibrosis and consequent heart failure. We have recently shown that cardiac fibrosis post-myocardial infarction (MI) can be regulated by resident cardiac cells with a fibrogenic signature and identified by the expression of PW1 (Peg3)....

Descripción completa

Detalles Bibliográficos
Autores principales: Bouvet, Marion, Claude, Olivier, Roux, Maguelonne, Skelly, Dan, Masurkar, Nihar, Mougenot, Nathalie, Nadaud, Sophie, Blanc, Catherine, Delacroix, Clément, Chardonnet, Solenne, Pionneau, Cédric, Perret, Claire, Yaniz-Galende, Elisa, Rosenthal, Nadia, Trégouët, David-Alexandre, Marazzi, Giovanna, Silvestre, Jean-Sébastien, Sassoon, David, Hulot, Jean-Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347632/
https://www.ncbi.nlm.nih.gov/pubmed/32647159
http://dx.doi.org/10.1038/s41598-020-68223-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347632/
https://www.ncbi.nlm.nih.gov/pubmed/32647159
http://dx.doi.org/10.1038/s41598-020-68223-8

Ejemplares similares